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DatabaseThe Minimal Interval Resonance Imaging in Alzheimer's Disease (MIRIAD) dataset is a series of longitudinal
volumetric T1 MRI scans of 46 mild–moderate Alzheimer's subjects and 23 controls. It consists of 708 scans
conducted by the same radiographer with the same scanner and sequences at intervals of 2, 6, 14, 26, 38 and
52 weeks, 18 and 24 months from baseline, with accompanying information on gender, age and Mini Mental
State Examination (MMSE) scores. Details of the cohort and imaging results have been described in
peer-reviewed publications, and the data are here made publicly available as a common resource for
researchers to develop, validate and compare techniques, particularly for measurement of longitudinal
volume change in serially acquired MR.
© 2013 Elsevier Inc. Open access under CC BY license. Introduction
Alzheimer's disease (AD) is an increasingly prevalent problem as
the population ages. StructuralMR imaging is a well established, widely
available, non-invasive tool for investigating the inevitable downstream
consequence of neurodegeneration in Alzheimer's disease—atrophy.
In the correct clinical context the presence of medial temporal lobe
atrophy on cross-sectional MR imaging has positive predictive value
for a diagnosis of AD and this is now incorporated in diagnostic criteria
(Dubois et al., 2007; McKhann et al., 2011). Quantiﬁcation of the rate
of global and regional brain volume loss from serially acquired MRI
is increasingly used both to understand the progression of the disease
and as an outcome measure for clinical trials, with the premise that
a disease-modifying therapy would be expected to slow the rate of
atrophy towards that seen in normal ageing (Fox and Schott, 2004).
Numerous methods for quantifying change between serial scans
have been proposed and are used both in observational and thera-
peutic studies. In the absence of a “gold standard” validating new
methods and comparing the performance of different algorithms are
not straightforward.
We announce here the public release of a longitudinal database
of structural (T1 contrast) MRI scans from the Minimal Interval
Resonance Imaging in Alzheimer's Disease (MIRIAD) study. Whilst
there are a number of other open imaging databases, including the
Alzheimer's Disease Neuroimaging Initiative (ADNI, Jack et al., 2010),license. the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing
(AIBL, Ellis et al., 2010) and Open Access Series of Imaging Studies
(OASIS, Marcus et al., 2010) the MIRIAD dataset has a number of fea-
tures making it ideal for methods development and validation. These
include:
1. all scans on the same scanner over the same time period;
2. multiple serial scans (up to nine over two years) for both AD and
controls;
3. a scanning schedule designed to give a wide range of inter-scan
intervals from 2 weeks to 2 years; and
4. back-to-back scanning at three time points.
These features allow for formal assessments of the symmetry,
transitivity and reproducibility ofmeasures of atrophy, and assessment
of bias (Fox et al., 2011). By making this dataset widely available, the
performance of different image analyses methodologies can be com-
pared directly; and novel tools can be validated before being applied
to other datasets.
Overview
TheMIRIAD studywas principallymotivated to establish theminimal
interval over which it would be feasible to undertake clinical trials in
Alzheimer's disease using atrophymeasured from serial MRI as an out-
come measure. Supplementary aims were:
1. To assess whether combining more than two scanning time points
would increase statistical power and, if so, the optimal combina-
tion and timing of scans for trials of varying lengths.
Table 2
Timing and attendance of visits.
Mean interval days from baseline
(SD)
0 16
(5)
43
(6)
98
(8)
180
(7)
Subjects (patients) scanned 68
(45)
66
(44)
67
(45)
68
(46)
66
(44)
Scans completed 133 66 130 68 66
Mean interval days from baseline
(SD)
270
(19)
365
(14)
552
(18)
730
(10)
Subjects (patients) scanned 60
(38)
67
(44)
39
(26)
22
(14)
Scans completed 117 67 39 22
Table 3
Publications featuring MIRIAD data.
Atrophy in dementia
Boyes et al. (2006) NeuroImage
Gutiérrez-Galve et al. (2009) Dement Geriatr Cogn
Ridgway et al. (2009) NeuroImage
Cardoso et al. (2009) MICCAI 2009
Anderson et al. (2012) Neurobiol Aging
Medial–temporal lobe atrophy
Barnes et al. (2005) Dement Geriatr Cogn
Barnes et al. (2007a) Neurobiol Aging
Barnes et al. (2007b) J Comput Assist Tomo
Ridha et al. (2007) Arch Neurol-Chicago
Barnes et al. (2008a) NeuroImage
Barnes et al. (2008b) Neurobiology
Barnes et al. (2010) NeuroImage
Leung et al. (2010) NeuroImage
Simulation studies
Schweiger et al. (2005) MICCAI 2005
Camara-Rey et al. (2006a) MICCAI 2006
Camara et al. (2006) IEEE T Med Imaging
Camara-Rey et al. (2006b) MICCAI 2006
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within a single day and over short intervals where changes in
individual's hydration and scanner ﬂuctuations, but not patholog-
ical atrophy, might be expected.
Details of subject demographics have been previously described
(Schott et al., 2006) and are summarised here in Table 1. In brief
the dataset includes 46 patients with a diagnosis of mild–moderate
probable AD (NINCDS–ADRDA, McKhann et al., 1984) all seen at the
Dementia Research Centre, Institute of Neurology, UCL, and 23 non-
demented control subjects, typically the patient's spouse or carer.
Inclusion criteria included age over 55 years and a mini-mental state
examination (MMSE, Folstein et al., 1975) score between 12 and 26/
30. Controls hadMMSE scores >26/30, and no history of cognitive im-
pairment, head injury, major psychiatric disease or stroke. Exclusion
criteria included any neurodegenerative disease (apart from AD for
the patients), or inability to tolerate MRI. At baseline and one year all
subjects underwent a detailed neuropsychometric and clinical evalua-
tion. MMSE score was recorded at baseline and 6-monthly intervals.
All subjects were requested to attend seven imaging visits at 0, 2, 6,
14, 26, 38 and 52 weeks from baseline. 39 subjects who completed
all these visits during the study attended a further scan at 18 months,
22 of these had a further scan at 24 months. At 0, 6 and 38 weeks two
back-to-back scans were conducted. Study attendance ﬁgures are
shown in Table 2. Ethical approval for the study (and subsequently
its release) was received from the local research ethics committee,
and written consent obtained from all participants.
All scans were conducted on the same 1.5 T Signa MRI scanner
(GE Medical systems, Milwaukee, WI) and acquired by the same radi-
ographer. Three-dimensional T1-weighted images were acquired
with an IR-FSPGR (inversion recovery prepared fast spoiled gradient
recalled) sequence, ﬁeld of view 24 cm, 256×256 matrix, 124 1.5 mm
coronal partitions, TR 15 ms, TE 5.4 ms, ﬂip angle 15°, TI 650 ms. A
total of 708 volumetric scans were acquired with up to 12 scans per
individual, 25 different interscan intervals, allowing for a total of
2199 scan-pairs for patients with AD and 1182 scan-pairs for controls.
Results to date
A list of published articles which have used (in full or in part) this
dataset is shown in Table 3. Amongst others, these have included a
number ofmethodological papers describing techniques for estimating
hippocampal atrophy using a hippocampal template and the boundary
shift integral (Barnes et al., 2007a), ﬂuid registration (Barnes et al.,
2007b), an automated medial temporal lobe scale (Ridha and Barnes,
2007) and label fusion methods (Leung et al., 2010). Clinical papers
have included assessments of hippocampal asymmetry in AD (Barnes
et al., 2005); the effect of APOE status on cortical thickness (Gutiérrez-
Galve et al., 2009); the correlation between rate of atrophy and change
in certain neuropsychological test scores (Schott et al., 2008); and the
demonstration that the use of afﬁne image registration (nine degrees
of freedom) can correct for longitudinal changes in voxel size (Whitwell
et al., 2004). These data have been used to compare methods for
automated calculation of volumes and atrophy in the hippocampus
(Barnes et al., 2008a), and atrophy measured using the boundaryTable 1
Demographics of the dataset.
Alzheimer's Disease
(N=46)
Controls
(N=23)
Age at study entry (years) 69.4±7.1 69.7±7.2
Men 41 (%) 52 (%)
Mean (SD) baseline MMSE 19.2±4 29.4±0.8shift integral with both Jacobian integration (Boyes et al., 2006), and
with both SIENA and SIENAX (Smith et al., 2007). For clinical trials,
the MIRIAD dataset has been used to estimate required sample sizes
for six-month AD clinical trials using ventricular expansion (Schott
et al., 2005) and hippocampal atrophy (Barnes et al., 2008a) as out-
come measures; and using grey matter atrophy (Anderson et al.,
2012). Using a multi-level model speciﬁcally designed to analyse this
data-set (Frost et al., 2004; Schott et al., 2006) provided a detailed
assessment of the mean whole brain rate of atrophy (2.23%/year, 95%
CI: 1.90–2.56%/year using the boundary shift integral implementation
at that time) and between- and within-subject sources of variance in
atrophy in AD trials (total variance 0.992+(0.82/t)2, from 2 scans ‘t’
years apart). Using these results they estimated sample sizes required
to power AD studies over intervals of 6, 12, and 24 months (with and
without drop-outs) using between 2 and 5 scanning time points
spaced either evenly or optimally. This model was subsequently ex-
tended to estimate whether estimating brain atrophy from a run-in
period could increase efﬁciency for clinical trials (Frost et al., 2008).Camara et al. (2007) MICCAI 2007
Camara et al. (2008) NeuroImage
Clinical trials design
Whitwell et al. (2004) Magn Reson Imaging
Schott et al. (2005) Neurology
Schott et al. (2006) J Neurol
Frost et al. (2008) Stat Med
Schott et al. (2008) Neuropsychologia
Methods comparison
Smith et al. (2007) NeuroImage
Clarkson et al. (2011) NeuroImage
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For the purposes of this data-release scans were converted from
DICOM to NIfTI-1 format using MRICron/dcm2nii1 and all identiﬁable
information removed in the process. Subjects were assigned a ran-
dom identiﬁer and the NIfTI ﬁles with a subject and visit identiﬁer
were placed in an Extensible Neuroimaging Archive Toolkit (XNAT,
Marcus et al., 2007) database. An archive containing all the images
was also prepared and placed on the XNAT system. For those visits
where MMSE scores were collected this information is also available.
The full dataset and terms of use will be available at http://miriad.drc.
ion.ucl.ac.uk/ from Friday 8th February 2013.
Discussion
We hope that the release of this dataset will provide the imaging
community—and particularly those interested in the accurate quanti-
ﬁcation of volume change from serially acquired MR—with a useful
common resource with which techniques can be developed, validated
and compared, prior to implementation on other datasets or for clinical
trials. Towards this goal this dataset has already been used in a blinded
form as part of the Medical Image Computing and Computer Assisted
Intervention (MICCAI) 2012 challenge “Atrophy Measurement Bio-
markers using Structural MRI for Alzheimer's Disease”.2 The release
of this dataset in an open form (together with the blinding codes
from the MICCAI challenge) will enable other workers to compare
their methods to workshop outcomes on the same dataset.
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